---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-311357"
form_type: "8-K"
ticker: "LBRX"
cik: "0001691082"
company_name: "LB PHARMACEUTICALS INC"
filed_at: "2026-07-22T12:14:47+00:00"
generated_at: "2026-07-22T12:20:11.443178+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# LB Pharma accelerates Phase 3 NOVA-2 topline to H1 2027; cash runway into Q2 2029

## Summary
- Topline results from Phase 3 NOVA-2 trial of LB-102 in schizophrenia now expected in first half of 2027, ahead of prior guidance.
- Pre-NDA meeting with FDA scheduled for second half of 2027.
- Cash runway expected to fund operations into Q2 2029 through multiple clinical readouts.
- Phase 2 ILLUMINATE-1 trial in bipolar depression topline expected in Q1 2028.
- Phase 2 trial of LB-102 in adjunctive MDD topline expected in first half of 2029.

## SEC filing metadata
- accession: 0001193125-26-311357
- form_type: 8-K
- ticker: LBRX
- cik: 0001691082
- company_name: LB PHARMACEUTICALS INC
- filed_at: 2026-07-22T12:14:47+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1691082/000119312526311357/0001193125-26-311357-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1691082/000119312526311357/d173035d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-311357
- JSON: https://secwatch.observer/filing/0001193125-26-311357.json
- Plain text: https://secwatch.observer/filing/0001193125-26-311357.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.